BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
Watch China's Shenzhou 22 rescue ship arrive at Tiangong space station (video)- Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- 7 Straightforward Moves toward Move Information from Your Old Cell phone to Your New One: A Thorough Aide
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- The Best Computer games Ever
- Artemis 2 moon rocket gets 'America 250' paint job | Space photo of the day for Dec. 23, 2025
- Medicine doesn’t just have ‘conscientious objectors’ − there are ‘conscientious providers,’ too
- Understanding climate change in America: Skepticism, dogmatism and personal experience
- Pick Your #1 Japanese Food
